Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Effect of Vitamin D Administration on Methotrexate Adverse Effects in Patients With Acute Lymphoblastic Leukemia
Since methotrexate toxicity represents a major problem in patients treating with cancer and there are few studies about the role of vitamin D in the pathogenesis of this toxicity, so the aim of the present study is investigation of the effect of vitamin D administration on methotrexate toxicity such as oral ulcerations, bone marrow toxicity as well as renal and hepatic toxicity also the role of inflammatory mediators and oxidative stress markers in methotrexate toxicity will be evaluated, taking in consideration the dose of leucovorin rescue.
Leukemia is a type of blood cancer that affects the body's white blood cells (WBCs). White
blood cells help fight infection and protect the body against disease, but in leukemia, some
of the white blood cells turn cancerous and don't work as they should. As more cancerous
cells form in the blood and bone marrow (spongy tissue inside the bones), there's less room
for healthy cells .
The different types of leukemia can be either acute (fast growing) or chronic (slow growing).
Acute lymphoblastic leukemia (ALL) happens when the body makes too many lymphoblasts (a type
of white blood cell). It's the most common type of childhood cancer.
Treatment outcome of acute leukemia has been improved recently using Methotrexate . Side
effects of methotrexate usually in the form of ulcerative stomatitis, leukopenia (lower
amount of white blood cells), nausea, abdominal discomfort, and elevated liver and kidney
function tests. Identifying risk factors leading to these side effects would be valuable to
develop preventive interventions and improve quality of life for these young patients.
Studies revealed a relationship between vitamin D deficiency and adverse reactions of
chemotherapy in cancer patients. This vitamin is important in many physiological processes in
the body as bone mineralization and immune regulations . A human body produces vitamin D as a
response to sun exposure. A person can also boost their vitamin D intake through certain
foods or supplements. .
Previous literature showed that receptors for vitamin D expressed in the mucosa and so there
is a relationship between vitamin D deficiency and increase inflammation and impairment of
mucosa .
Vitamin D is a fat-soluble vitamin that not only regulates calcium absorption and bone
metabolism, but can also regulate cell proliferation, differentiation and the immune
response, vitamin D insufficiency/deficiency is associated with poor clinical outcome and
significantly worse progression free survival of patients from leukemia and lymphoma.
Calcium is the most abundant element in the human body and is essential for life. It has a
key role in many physiological processes including skeletal mineralization, muscle
contraction, nerve impulse transmission, blood clotting, and hormone secretion . 1,
25-Dihydroxyvitamin D3 the active form of vitamin D plays major role in intestinal calcium
absorption, Calcium homeostasis is also regulated by parathyroid hormone.
Patients with acute lymphoblastic leukemia may be at risk of vitamin D deficiency because of
impaired vitamin intake and sunlight exposure .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT02257684 -
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
|
Phase 2 |